



PCT/GB 2003 / 0 0 5 6 7 0



INVESTOR IN PEOPLE

RECEIVED	
03 FEB 2004	
WIPO	PCT

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

PRIORITY DOCUMENT


SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed *AmBrewster*

Dated 20 January 2004

Patents Form 1/77

Patents Act 1977
(Rule 16)

The
Patent
Office



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference	444.76767/001	280EL02 E773699-1 000021 P01/7700 0.00-0230152.1	
2. Patent application number (The Patent Office will fill in this part)	0230152.1	24 DEC 2002	
3. Full name, address and postcode of the or of each applicant (underline all surnames)	Sinvent AS S P Andersens vei 5 N-7465 Trondheim Norway		
Patents ADP number (if you know it)			
If the applicant is a corporate body, give country/state of incorporation	Norway		
4. Title of the invention	Product		
5. Name of your agent (if you have one)	Frank B. Dehn & Co.		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	179 Queen Victoria Street London EC4V 4EL		
Patents ADP number (if you know it)	166001 ✓		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	Yes		

07786411 002

Patents Form 1/77

9 Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0

Description 15

Claim(s) 2

Abstract 0

Drawing(s) 0

10. If you are also filing any of the following, state how many against each item.

Priority documents -

Translations of priority documents -

Statement of inventorship and right to grant of a patent (Patents Form 7/77) -

Request for preliminary examination and search (Patents Form 9/77) -

Request for substantive examination (Patents Form 10/77) -

Any other documents (please specify) -

11. I/We request the grant of a patent on the basis of this application.

Signature

Date 24 December 2002

Frank B. Dehn & Co.

12. Name and daytime telephone number of person to contact in the United Kingdom

Julian Cockbain
020 7206 0600

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645-500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s) of the form. Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes', Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

76767001.619

Product

The present invention relates to reconstitutable dried blood products, processes for their preparation and reconstitution, and their medical and non-medical (e.g. research) uses.

Hospitals carry stocks of blood products (e.g. erythrocyte concentrates, platelets, plasma, etc.) for use for example during surgical procedures. Blood products containing anuclear blood cells (i.e. cells without nuclei, such as erythrocytes and platelets) deteriorate rapidly. Platelets degrade very quickly as they are stored at ambient temperature and erythrocytes deteriorate very rapidly if not chilled and stored in refrigerators at about 1 to 4°C. Even refrigerated, such blood products deteriorate and must be discarded after a short time, e.g. three to six weeks for erythrocytes (red blood cells) or four hours to seven days for platelets, as the anuclear cells have died, deteriorated or substantially disappeared or as the risk of bacterial infection has increased to an unacceptable level.

Health authorities and hospitals thus generally rely on a continuous collection, separation and storage of blood to meet their normal needs, and in order to maintain supplies at maximum levels, surgeons demanding blood products are routinely supplied with the oldest supplies still within their permitted storage times, i.e. supplies in sub-optimal condition. Where supplies ~~are insufficient to meet demand, e.g. in the case of an~~ event with many casualties or where an individual with a rare blood group is in need of large quantities of a compatible blood product, fresh supplies need to be transported from remote locations, thereby risking patients' lives if opportunities for supply and transport are restricted.

As a result, in the case of a major accident or of an event with large numbers of casualties, hospitals and health authorities risk having an inadequate supply of blood products available for transfusions. In such circumstances, the hospitals and health authorities cannot rely upon being able to recruit donors and to collect sufficient blood within the necessary time - not least because the donors' blood must be checked for any disease (e.g. HIV infection) before it is used.

While it is possible to cryogenically store certain cells for long periods, e.g. in liquid nitrogen at -196°C , this is not true for anuclear cells unless exogenous cryoprotectants and complex and expensive freezing and reconstitution processes are used. Such procedures are not only complex but are not generally applicable for disaster areas or areas of military conflict where the necessary continuous and reliable supplies of electricity and liquid nitrogen will not normally be available.

Conventional freezing techniques are quite simply not feasible for anuclear cell-containing blood products. Thus for example W. Tousel, in the discussion appended to his paper with H. Hindorf in "Principes et applications de la lyophilisation des produits biologiques, pharmaceutiques et alimentaires", Science et Technique du Froid, Tokyo, Japan, 1985, pages 287-292, when asked whether he had experience of freeze-drying such products replied "It is not possible to freeze dry such sensitive blood cells as platelets and erythrocytes. These cells can be preserved by liquid preservation such as the liquid nitrogen method with some cell loss". The same discussion advised that red blood cells could be preserved by freezing at -28°C with a glycerol content of 25% or by other freezing techniques using temperatures between -196°C and -80°C .

The use of glycerol or other cryoprotectants is clearly undesirable as they must be removed before the

blood product is administered by transfusion and, as mentioned above, cryogenic techniques require complex and expensive equipment, materials and processes which are generally not available or feasible at disaster sites (e.g. earthquake, volcano or major accident sites) or during military operations.

There is thus a need for such blood products which can be stored for periods longer than is currently possible and yet can be rapidly reconstituted for transfusion into a patient when the need arises, e.g. when supplies of blood products of the correct type are exhausted. Moreover there is an additional demand for blood products that are a safer and more reliable alternative to the materials currently available for transfusions. Furthermore, the logistics for blood products both in remote regions and large urban centres are complicated by the bulk of the current products and their refrigeration requirements.

We have now surprisingly found that it is possible to produce dried anuclear cell-containing blood products, to store these under ambient conditions or relatively mild refrigeration, and to reconstitute the products to produce a transfusion fluid containing viable cells even after storage periods significantly in excess of the maximum storage period for equivalent refrigerated blood products.

Thus viewed from one aspect the invention provides a dried particulate blood product the particles whereof comprise anuclear blood cells in a macromolecular protective material.

~~---The dried product, on dissolution in a---~~
physiologically tolerable aqueous solution to an osmolality within the range normal for the relevant species' blood and at a temperature within 1°C of the normal day time body temperature of the relevant species, contains intact viable cells.

Viewed from a further aspect the invention provides

a process for the preparation of a dried particulate blood product the particles whereof comprise anuclear blood cells in a protective agent, said process comprising:

- obtaining a blood sample from a mammalian (e.g. human) subject;
- adding an anticoagulant to said sample;
- concentrating the cells of said sample;
- recovering a concentrate containing anuclear blood cells from said sample;
- impregnating with said concentrate a particulate comprising a macromolecular protective material;
- drying the impregnated particulate at a temperature in the range -20 to $+120^{\circ}\text{C}$ (preferably -10 to $+40^{\circ}\text{C}$ but up to 120°C is feasible for high temperature driers); and optionally
- packaging the dried particulate in sealed containers, especially containers substantially free of oxygen in any head space, e.g. by vacuum packing.

The macromolecular protective material used in the invention is preferably a material containing a water-soluble macromolecular substance having a molecular weight in excess of 1000 D, especially above 2000 D and more especially a mixture of such substances. The material preferably contains macromolecules endogenous to the species from which the blood derives, in particular materials selected from polysaccharides, proteins (including glycoproteins) and lipids (e.g. phospholipid). Especially preferably the material contains macromolecules naturally occurring in the blood of the species from which the blood derives, e.g. plasma proteins, intracellular proteins, and cell membrane molecules (e.g. proteins and lipids, etc). More especially preferably the material comprises cell membrane molecules from anuclear blood cells, in particular erythrocytes. Especially preferably, the material comprises spectrin. In an especially preferred

embodiment, the protective material is substantially haemoglobin-free, e.g. with a haemoglobin content of less than 50% wt, preferably less than 25% wt, more preferably less than 10% wt, especially less than 1% wt relative to the haemoglobin content of erythrocytes (on a dry solids basis).

The drying of the impregnated particulate is preferably effected at a temperature in the range -5 to +37°C, more especially -1 to 25°C, particularly 0 to 15°C, more particularly 1 to 10°C, e.g. 3 to 5°C. The duration of the drying process will depend upon the drying technique used but will preferably not exceed 10 hours. A drying period of up to 8 hours is preferred.

Drying is preferably effected so as to achieve a total moisture content in the dried product of 1 to 20% wt, more preferably 2 to 17% wt.

Drying may be effected by any suitable procedure, e.g. vacuum drying, spray drying, fluidized bed drying, rotary drying, agitated bed drying, continuous belt drying, etc. However the technique used is preferably one which subjects the cells to a minimum of physical stress and accordingly fluidized bed drying is especially preferred.

In the drying procedure, conventional drying media (e.g. air, nitrogen, etc.) may be used; however it is preferred to use nitrogen, reduced oxygen content air, or noble gases.

The gas pressure in the drying procedure is preferably within 10% of ambient air pressure.

The particles that are impregnated in the process ~~of the invention are preferably in solid or gel form,~~ particularly solid form. The particle size (i.e. mode particle diameter) is preferably in the range 0.05 to 5 mm, more especially 0.5 to 3 mm. Accordingly, if desired the particles may be graded (e.g. sieved) before use to select particles of the desired size. Substantial uniformity of particle size results in

substantially uniform drying of the impregnated particles and thus minimizes the stress to which the anuclear cells are exposed during drying.

Impregnation of the particles may be achieved by any suitable method, e.g. by spraying or dripping the concentrate onto the particles, by immersing the particles in the concentrate, or by passing a curtain of falling concentrate over the particles (i.e. by moving the curtain or the particles or both). Preferably a technique is used which exposes the anuclear cells to minimal mechanical stress, e.g. dripping or using a falling curtain. If desired the particles may be agitated during the impregnation procedure, e.g. mechanically or by gas flow (as for example in a vibrated or fluidized bed).

The particles used are desirably porous (e.g. with a pore size or interstitial gaps in excess of 10 μm) and/or water-swellable.

Particle impregnation may alternatively, but less preferably, be effected by mixing the concentrate with a solution of the protective material and gelling droplets of the resulting mixture, e.g. by dripping or spraying the mixture into an environment in which the mixture forms a gel, e.g. a solution which contains an agent which interacts with a component of the mixture to form a gel. Thus for example the mixture may include an alginate and on dripping or spraying into a calcium salt solution this will form droplets of a gel.

In an alternative aspect of the invention the particulate protective material may be impregnated with ~~a liquid (generally aqueous) solution, dispersion or~~ suspension of nucleus-containing eukaryotic cells (preferably mammalian cells, in particular human cells) and/or of blood proteins (e.g. by impregnation with plasma) and then dried to produce a reconstitutable biological product.

Viewed from a further aspect therefore the

invention provides a dried, reconstitutable biological product comprising nucleus-containing eukaryotic cells and/or blood proteins and/or blood lipids in a macromolecular protective material.

Viewed from a still further aspect the invention provides a process for the preparation of a dried, reconstitutable biological product which process comprises impregnating a particulate macromolecular protective material with a liquid containing nucleus containing eukaryotic cells and/or blood proteins and/or blood lipids, and drying the impregnated particulate.

Especially preferably the reconstitutable biological product (i.e. a product which can be rehydrated to a material with the desired biological activity) is dried plasma or a dried stem cell product.

The anticoagulant used in the process of the invention is preferably one which inhibits cell aggregation and/or one which operates to inhibit fibrin formation. One example of a suitable anticoagulant is citrate. The use of anticoagulants following blood collection for the preparation of transfusable blood products is a conventional practice. Typical anticoagulants used in practice include CPD, CP2D, CPDA-1, AS-1, AS-3 and AS-5.

The cell concentration step in the process of the invention may be any suitable cell concentration procedure, e.g. filtration. However centrifugation is preferably used. Centrifugation is conventionally used following blood donation to produce blood cell concentrates and cell-free plasma which are separated before being stored. Centrifugation, optionally several cycles of centrifugation, is also conventionally used to produce concentrates of the different types of cells found in blood, e.g. erythrocytes, platelets, granulocytes, monocytes, lymphocytes, B cells, T cells and NK cells, as in certain surgical procedures (e.g. organ transplantation) it is not always desirable for

the cell-containing transfusion fluid to contain the different types of cells in their normal ratios. The cell-containing concentrate used in the process of the present invention may contain platelets and/or erythrocytes and optionally other blood cells and blood proteins, etc. Preferably however it contains nucleus-containing cells at an abundance relative to the anuclear cells which is less than that in blood. To this end the cell concentration step may involve several cycles of centrifugation, separation, dilution, centrifugation, etc. so as to increase the relative abundance of the desired cell types in the final concentrate. In general, particularly in preparing a red blood cell product, it may be desirable to reduce leucocyte and cytokine concentration before centrifugation, e.g. by using an in-line leucocyte reduction filter (available from Baxtor Healthcare)..

Following cell concentration, the concentrate may be stored under refrigeration (e.g. 1 to 4°C) for up to 35 days before further processing. However the concentrate is preferably further processed with minimal delay, preferably no more than 7 days, more preferably no more than 24 hours.

To optimize the viability of the cells in the blood products of the invention, it is desirable that there should be as little delay as possible between blood collection and the product drying stage and that during any period between process steps the intermediate product be stored under refrigeration (e.g. 1 to 4°C).

While the invention is applicable to blood from all ~~animals having a vascular system, it is especially~~ applicable to mammalian blood, and in particular human blood.

In the sample collection stage, blood is preferably collected from healthy donors, e.g. using international recommendations from the relevant health authorities or, in Norway, from the Norwegian Health Ministry.

Typically, for human blood, the sample volume per donor will be in the range of 100 to 800 mL, more preferably 200 to 600 mL, e.g. 400 to 500 mL, especially 440 to 480 mL. Blood from the donor will preferably be screened for infection, especially viral infection, in particular hepatitis B, hepatitis C and HIV. Where screening shows the blood to be infected, the sample should be rejected, unless the dried product is designated for the use of the donor only. Generally however all infected samples will be rejected. Nonetheless, since the dried products according to the invention are more readily susceptible to a range of decontamination techniques than whole blood or liquid blood component samples, e.g. irradiation, gas exposure, etc., it may not be necessary to reject blood samples found to contain disease markers. The blood should be collected, stored and handled under sterile conditions and using sterile equipment. To the collected blood should be added an anticoagulant as mentioned above. Typically for a 450 mL sample of blood this might involve collection into 63 mL of a sterile aqueous citrate/phosphate/dextrose solution (e.g. CPD, CP2D or CPDA-1). If the sample is not to be further processed immediately it is desirably stored under refrigeration, e.g. at 1-4°C. Blood collection is described for example in Chapter 11 of Basic and Applied Concepts of Immunohematology by Blaney et al, Mosby, 2000.

The sample is then subjected to cell concentration, e.g. using a conventional centrifuge. The resulting cell suspension may then be processed further

~~immediately or stored under refrigeration (e.g. 1-4°C)~~ for up to five weeks before further processing.

The cell concentration step may if desired be used to collect all blood cell types; however if desired only specific blood cell types, e.g. erythrocytes, platelets, stem cells, granulocytes or lymphocytes may be collected if the final product is desired to contain such specific

cells rather than the whole spectrum of blood cells.

The plasma may if desired also be collected and further processed to collect blood proteins (e.g. plasma proteins, in particular gamma globulins and albumin and coagulation factors) and cellular constituent materials, etc. which can similarly be transformed into a reconstitutable, dried, particulate blood product. Alternatively such materials may be collected and concentrated using other techniques, e.g. affinity chromatography and other known separation techniques.

Particularly where the cell concentration step is used to separate cells with nuclei from those without, the concentrate may then be sterilized using techniques lethal to cells with nuclei, e.g. irradiation, etc. This can be done on the concentrate or on the product at any subsequent stage in its preparation, packaging and storage.

The dried particulate blood product is conveniently packaged into containers which are then sealed. Preferably the gas in the sealed containers is oxygen-free, e.g. nitrogen or helium. The sealed containers may be stored at ambient temperature but desirably are stored frozen or under refrigeration or freezing, e.g. -20 to +10°C, preferably -10 to +4°C.

The dried product may be reconstituted by mixing with a sterile aqueous solution, preferably one which, in combination with the dried product, will yield a solution which is within 10% of being iso-osmolar with blood, e.g. corresponding to 0.8 to 1.0% saline. Particularly desirably, the reconstitution fluid contains the major metal cations present in plasma, i.e. sodium, calcium, potassium and magnesium. Also desirably the reconstitution fluid contains glucose, adenosine triphosphate and 2,3-diphosphoglycerate.

In order to optimize storage and reconstitution, the mean particle size (expressed for example in $D(v, 0.5)$) for the protective material particles which are

impregnated in the process of the invention is preferably in the range 0.05 to 5 mm, especially 0.5 to 3 mm. If necessary therefore, the protective material may be sized, e.g. sieved, to select a particulate fraction having particle sizes of the desired magnitude.

Where the protective agent used in the preparation of the dried blood product is not physiologically tolerable in the quantities used, reconstitution will involve complete or partial removal of the protective agent. To achieve this, the product may be dissolved in the reconstitution fluid and then centrifuged one or more times with the sedimented cells being recovered and diluted with further reconstitution fluid.

Alternatively the dissolved product may be filtered with the retentate, i.e. the cells, being recovered and if necessary diluted with further reconstitution fluid. In another alternative procedure, the dissolved product may be dialysed using a membrane which permits transfer of the protective agent.

Thus viewed from a further aspect the invention provides a method of production of a transfusion liquid, said method comprising dispersing a dried particulate blood product according to the invention in a physiologically tolerable sterile aqueous solution and if necessary treating the resulting dispersion to reduce the content therein of the protective material.

Viewed from a further aspect the invention provides a kit comprising a first container containing a dried particulate blood product according to the invention, and a second container containing a sterile physiologically tolerable aqueous reconstitution solution.

Where it is desired that the transfusion liquid contain more than one type of blood component, e.g. erythrocytes, platelets, and plasma proteins, it is possible to use a combination of separately produced dried blood products, e.g. one containing erythrocytes

and a second containing plasma proteins. The combination may be brought together before or after reconstitution. Mixing before reconstitution is feasible where the protective materials used do not have to be removed or where they may be removed without separating the different blood products. Thus for example, where a protective material has a low molecular weight, e.g. below 500 D, centrifugation or dialysis might be used. For this purpose a conventional blood cell processor may be used.

The process of the invention is especially suited to the production of such combination transfusion fluids. Thus centrifugation of the original blood sample may be effected in a series of stages, at each successive stage using a higher g-force whereby to separate out progressively lower weight blood components. As a result, to collect plasma proteins for example, g-forces which would cause erythrocytes to rupture may be used since by this stage the sample will be cell-free.

Thus while the invention is primarily directed to the production of dried, anuclear cell-containing particulate products, as mentioned above it may also be used to produce dried particulates containing other blood components, especially proteins (e.g. plasma proteins), cell fragments and other cell constituents. A particularly desirable such product is reconstitutable dried plasma. The invention may also be used to produce dried particulate compositions containing mammal cells other than blood cells, e.g. bone marrow cells, foetal or embryonic cells (especially stem cells), etc. Especially preferably the product contains mesenchymal stem cells (MSC), e.g. from adult bone marrow, or hematopoietic stem cells from peripheral blood. MSCs are particularly useful since they are less subject to rejection by recipients. Such products, their production and their use also form aspects of the

present invention.

Using the procedure of the invention it is possible to produce dried products containing cells which are still viable after more than four months and even up to 10 years after removal from the body.

A further advantage of the dried product of the invention, besides its prolonged shelf life, is the fact that it requires less storage space than whole blood. Thus large quantities can be stored or moved to a location where a demand for blood has arisen, more easily than whole blood. For dried plasma there is the added advantage that it need not be stored frozen and hence need not be thawed before use.

The invention will now be described further with reference to the following non-limiting Examples.

Example 1

Preparation of macromolecular protective material

Frozen red blood cell concentrate was cooled further in liquid nitrogen, warmed to -25°C , and then grated. The resulting particulate was sieved to a particle size 0.5 to 2 mm. The particulate was vacuum freeze dried at -30°C to yield a dry powder. This was warmed to 20°C and stored.

Further powder was prepared analogously by fluidized bed drying at -20°C and by using both drying techniques on material for which the liquid nitrogen treatment was omitted.

Example 2

Preparation of dried erythrocyte containing product

At 2°C , a liquid red blood cell concentrate (prepared by

centrifugation of citrated blood) was dripped onto the powder of Example 1. The resulting impregnated powder was then dried in a fluidized bed dryer at 4°C over 6 hours to a moisture content of about 8% wt.

Example 3

Reconstitution of dried, erythrocyte containing product

100 μ L of phosphate buffered saline was added to approximately 4 μ L of a dried erythrocyte-containing product produced as described in Example 2 and having particle sizes in the range 0.01 to 5 mm. The product had been vacuum packed and stored under ambient conditions for more than 120 days since blood collection. Viewed under a light microscope (Reichert, Austria) after about 5 minutes, the reconstituted suspension was seen to contain cells.

Example 4

Production of haemoglobin free protective material

Concentrated red blood cells are diluted with water for injections so as to cause the cells to lyse. If desired a bipolar electrical field (e.g. having a voltage gradient in excess of 1000 V/cm) may be applied to cause cellular electrophoresis. The dilute mixture is centrifuged or ultra-centrifuged and the macrostructure/macromolecule fraction below the haemoglobin band is separated out. The separated fraction is again diluted with water for injections and centrifuged. This is repeated until the separated fraction no longer has the red colour associated with haemoglobin or has a colour which is much reduced in intensity. The separated fraction is then solidified by freezing, pulverized, sieved and dried as in Example 1.

The resulting powder may then be used as in Examples 2 and 3.

Example 5

Preparation of dried plasma or plasma components

Plasma (or a plasma component separated by centrifugation of plasma) is evaporated off under vacuum at ambient temperature until the remaining liquid is viscous. This is then applied to the protective material of Example 1 or 4 and dried analogously to Example 3.


Claims

1. A dried particulate blood product the particles whereof comprise anuclear blood cells in a macromolecular protective material.
2. A process for the preparation of a dried particulate blood product the particles whereof comprise anuclear blood cells in a protective agent, said process comprising:
 - obtaining a blood sample from a mammalian subject;
 - adding an anticoagulant to said sample;
 - concentrating the cells of said sample;
 - recovering a concentrate containing anuclear blood cells from said sample;
 - impregnating with said concentrate a particulate comprising a macromolecular protective material;
 - drying the impregnated particulate at a temperature in the range -20 to +120°C; and optionally
 - packaging the dried particulate in sealed containers.
3. A dried, reconstitutable biological product comprising nucleus-containing eukaryotic cells and/or blood proteins and/or blood lipids in a macromolecular protective material.
4. A process for the preparation of a dried, reconstitutable biological product which process comprises impregnating a particulate macromolecular protective material with a liquid containing nucleus containing eukaryotic cells and/or blood proteins and/or blood lipids, and drying the impregnated particulate.
5. A method of production of a transfusion liquid, said method comprising dispersing a dried particulate blood product according to claim 1 or claim 3 in a

physiologically tolerable sterile aqueous solution and if necessary treating the resulting dispersion to reduce the content therein of the protective material.

6. A kit comprising a first container containing a dried particulate blood product according to claim 1 or claim 3, and a second container containing a sterile physiologically tolerable aqueous reconstitution solution.

7. A kit as claimed in claim 6 wherein said first container is disposed in said second container and is openable whereby to release its contents into said solution.



THE PATENT OFFICE
21 JAN 2004
Received in Patents
International Unit